A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza

Vaccine

Volumn 28, Issue 45, 2010, Pages 7337-7343

  Kung, Hsiang Chi ^a   Huang, Kuo Chin ^a   Kao, Tsui Mai ^a   Lee, Yi Chien ^a   Chang, Feng Yee ^b   Wang, Ning Chi ^b   Liu, Yung Ching ^c   Lee, Wen Sen ^d   Liu, Hsing Jin ^d   Chen, Chin I ^d   Chen, Chien Hui ^e   Huang, Li Min ^a   Hsieh, Szu Min ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e Taiwan Product Quality Research Institute   (Taiwan)

Author keywords

2009 Pandemic influenza A (H1N1); Immune response; Vaccination

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CHEST TIGHTNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG FEVER; DRUG SAFETY; ECCHYMOSIS; EYE DISEASE; FACE EDEMA; FEMALE; HEADACHE; HEMAGGLUTINATION; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LIMB MOVEMENT; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NOSE CONGESTION; PAIN; PANDEMIC INFLUENZA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SORE THROAT; SWELLING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY FORMATION; EPIDEMICS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TAIWAN; VACCINATION; YOUNG ADULT;

EID: 77957753780     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.073     Document Type: Article

References (20)

1. Update: swine influenza A (H1N1) infections-California and Texas, April 2009. MMWR Morb Mortal Wkly Rep 2009, 58(16):435-437.
2. Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009, 58(15):400-402.
3. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009, 84(25):249-257.
4. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20):1945-1952.
5. World Health Organization. Availability of a candidate reassortant vaccine virus for the novel Influenza A (H1N1) vaccine development X-179A (accessed July 20, 2010, at ). http://www.who.int/csr/resources/publications/swineflu/candidates_X-179a/en/index.html.
6. Talbot H.K., Keitel W., Cate T.R., Treanor J., Campbell J., Brady R.C., et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008, 26(32):4057-4061.
7. European Committee for Proprietary Medicinal Products Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96) 1997, European Agency for the Evaluation of Medicinal Products, London.
8. Center for Biologics Evaluation and Research Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines 2007, May, Food and Drug Administration, Bethesda, MD.
9. European Committee for Proprietary Medicinal Products Guideline on dossier structure and content for pandemic influenza vaccine marketing authorization application (CPMP/VEG/4717/03) 2004, European Agency for the Evaluation of Medicinal Products, London.
10. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(25):2405-2413.
11. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoché M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(9708):41-48.
12. Roman F., Vaman T., Gerlach B., Markendorf A., Gillard P., Devaster J.M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010, 28(7):1740-1745.
13. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
14. Bocchini J.A., Bernstein H.H., Bradley J.S., Brady M.T., Byington C.L., Dennehy P.H., et al. Prevention of influenza: recommendations for influenza immunization of children, 2007-2008. Pediatrics 2008, 121(4):e1016-e1031.
15. Gross P.A., Weksler M.E., Quinnan G.V., Douglas R.G., Gaerlan P.F., Denning C.R. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 1987, 25(9):1763-1765.
16. Levine M., Beattie B.L., McLean D.M. Comparison of one- and two-dose regimens of influenza vaccine for elderly men. CMAJ 1987, 137(8):722-726.
17. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(25):2414-2423.
18. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303(1):37-46.
19. Del Giudice G., Stittelaar K.J., van Amerongen G., Simon J., Osterhaus A.D., Stöhr K., et al. Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci Transl Med 2009, 1(12). 12re1.
20. Gasparini R., Schioppa F., Lattanzi M., Barone M., Casula D., Pellegrini M., et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010, 64(4):432-438.